Evidence map›Paper›PMID 35196515›Full record

ArticleAmerican journal of human genetics2022

GWAS of longitudinal trajectories at biobank scale.

Seyoon Ko, Christopher A German, Aubrey Jensen, Judong Shen, Anran Wang, Devan V Mehrotra, Yan V Sun, Janet S Sinsheimer, Hua Zhou, Jin J Zhou

Open access · bronzeAbstract read
In one paragraph

Article in American journal of human genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. SPANature communications · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Seyoon KoDepartment of Computational Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Christopher A GermanDepartment of Biostatistics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Aubrey JensenDepartment of Biostatistics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Judong ShenBiostatistics and Research Decision Sciences, Merck & Co., Inc., Kenilworth, NJ 07033, USA.
Anran WangBiostatistics and Research Decision Sciences, Merck & Co., Inc., Kenilworth, NJ 07033, USA.
Devan V MehrotraBiostatistics and Research Decision Sciences, Merck & Co., Inc., Kenilworth, NJ 07033, USA.
Yan V SunDepartment of Epidemiology, Emory University, Atlanta, GA 30322, USA.
Janet S SinsheimerDepartment of Computational Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Human Genetics, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Hua ZhouDepartment of Computational Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA 90095, USA. Electronic address: huazhou@ucla.edu.
Jin J ZhouDepartment of Biostatistics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ 85721, USA. Electronic address: jinjinzhou@ucla.edu.
University of California, Los Angeles · USMerck & Co., Inc., Rahway, NJ, USA (United States) · USEmory University · USUniversity of Arizona · US

Funding

Genomics, GPUs, and Next Generation Computational StatisticsR01HG006139 · NHGRI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SOBEL, ERIC · 2011 to 2023
$5.1M
Multi-omic Predictors of Renal Function among HIV-infected Individuals of African AncestryR01DK125187 · NIDDK · EMORY UNIVERSITY · PI MARCONI, VINCENT CHARLES, SUN, YAN · 2020 to 2024
$4.1M
Modeling, Inference, and Optimization for Genomic and Biomedical Big DataR35GM141798 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LANGE, KENNETH L · 2021 to 2025
$2.7M
Integrative approaches for mapping the genetic risk of complex traitsR01HG009120 · NHGRI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PASANIUC, BOGDAN · 2017 to 2021
$2.3M
Develop T2D Patient-Centered Treatment Suggestion Rule using EMR dataK01DK106116 · NIDDK · UNIVERSITY OF ARIZONA · PI ZHOU, JIN · 2016 to 2019
$524k
A Role for Glycemic Variation in Optimizing Management of Diabetes and Vascular ComplicationsR21HL150374 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REAVEN, PETER D, ZHOU, JIN · 2020 to 2021
$250k
BLRD VA I01 BX005831NHGRI NIH HHS R01 HG006139NHGRI NIH HHS R01 HG009120NHLBI NIH HHS R21 HL150374NIDDK NIH HHS K01 DK106116NIDDK NIH HHS R01 DK125187NIGMS NIH HHS R35 GM141798
6 · The paper itself

Abstract

Biobanks linked to massive, longitudinal electronic health record (EHR) data make numerous new genetic research questions feasible. One among these is the study of biomarker trajectories. For example, high blood pressure measurements over visits strongly predict stroke onset, and consistently high fasting glucose and Hb1Ac levels define diabetes. Recent research reveals that not only the mean level of biomarker trajectories but also their fluctuations, or within-subject (WS) variability, are risk factors for many diseases. Glycemic variation, for instance, is recently considered an important clinical metric in diabetes management. It is crucial to identify the genetic factors that shift the mean or alter the WS variability of a biomarker trajectory. Compared to traditional cross-sectional studies, trajectory analysis utilizes more data points and captures a complete picture of the impact of time-varying factors, including medication history and lifestyle. Currently, there are no efficient tools for genome-wide association studies (GWASs) of biomarker trajectories at the biobank scale, even for just mean effects. We propose TrajGWAS, a linear mixed effect model-based method for testing genetic effects that shift the mean or alter the WS variability of a biomarker trajectory. It is scalable to biobank data with 100,000 to 1,000,000 individuals and many longitudinal measurements and robust to distributional assumptions. Simulation studies corroborate that TrajGWAS controls the type I error rate and is powerful. Analysis of eleven biomarkers measured longitudinally and extracted from UK Biobank primary care data for more than 150,000 participants with 1,800,000 observations reveals loci that significantly alter the mean or WS variability.

Indexed as

Biological Specimen BanksGenome-Wide Association StudyBiomarkersCross-Sectional StudiesElectronic Health RecordsHumansLongitudinal StudiesBiomarkersbiobankbiomarkersdisease progressionelectronic medical recordslongitudinaltrendvariationswithin-subject variability

Identifiers

PMID35196515
PMCPMC8948167
OpenAlexW4214501743

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.